中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

225 records (took 0.022 seconds)

    1.
    发明专利
    未知

    公开(公告)号：ES2174919T3

    公开(公告)日：2002-11-16

    申请号：ES95904415

    申请日：1994-12-21

    Applicant: BASF AG

    Inventor： LUBISCH WILFRIED ,  BEHL BERTHOLD ,  HOFMANN HANS PETER

    IPC: A61K31/495 ,  C07D401/14 ,  C07D403/04

    Abstract: PCT No. PCT/EP94/03839 Sec. 371 Date Jun. 20, 1997 Sec. 102(e) Date Jun. 20, 1997 PCT Filed Dec. 21, 1994 PCT Pub. No. WO96/19476 PCT Pub. Date Jun. 27, 1996Quinoxaline-2,3-(1H,4H)-diones of the formula I I and their tautomeric and enantiomeric forms and their physiologically tolerated salts, the variables R, R1 and R2 have the meanings specified in claim 1, and are useful for therapeutic treatment of neurodegenerative disorders, neurotoxic disturbances or as antiepileptics, antidepressants and anxiolytics; and drugs composed thereof.

    3.
    发明专利
    未知

    公开(公告)号：AT188214T

    公开(公告)日：2000-01-15

    申请号：AT95935894

    申请日：1995-10-02

    Applicant: BASF AG

    Inventor： LUBISCH WILFRIED ,  VIERLING MICHAEL ,  BEHL BERTHOLD ,  HOFMANN HANS PETER

    IPC: A61K31/495 ,  A61P25/00 ,  A61P43/00 ,  C07D403/04 ,  C07D241/00 ,  C07D207/00

    Abstract: PCT No. PCT/EP95/03902 Sec. 371 Date Mar. 27, 1997 Sec. 102(e) Date Mar. 27, 1997 PCT Filed Oct. 2, 1995 PCT Pub. No. WO90/11922 PCT Pub. Date Apr. 25, 1996Pyrrolyltetrahydrobenzoquinoxalinediones of the formula I I and their tautomeric and isomeric forms, and their physiologically tolerated salts, in which the variables have the meanings stated in the description, and the preparation thereof are described. The novel compounds are antagonists of the glutamate receptor subtypes and are thus suitable for controlling various diseases.

    7.
    发明专利
    未知

    公开(公告)号：TR199900503T2

    公开(公告)日：1999-07-21

    申请号：TR9900503

    申请日：1997-08-22

    Applicant: BASF AG

    Inventor： STEINER GERD ,  LUBISCH WILFRIED ,  BACH ALFRED ,  EMLING FRANZ ,  WICKE KARSTEN ,  TESCHENDORF HANS-JUERGEN ,  BEHL BERTHOLD ,  KERRRIGAN FRANK ,  CHEETHAM SHARON

    IPC: A61K31/435 ,  A61K31/519 ,  A61P25/24 ,  A61P43/00 ,  C07D211/00 ,  C07D239/00 ,  C07D333/00 ,  C07D495/14 ,  A61K31/445

    Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine compound of formula IwhereinR1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl,R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring,A is NH or oxygen,B is hydrogen or methyl,C is hydrogen, methyl or hydroxyl,X is nitrogen,Y is CH2, CH2-C2, CH2-C2-CH2 or CH2-CH,Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, andn is 2, 3 or 4,or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.

Patent Agency Ranking